Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

Post by MinimumDamageon Mar 03, 2021 10:19pm

157 Views

Post# 32712105

Who owns or owned Beetlebung? Salzman grou

BEETLEBUNG PHARMA

Salzman Capital Ventures founded Beetlebung Pharma Ltd. in 2017 focused on the discovery and development of novel pharmaceuticals for treatment of pain. In 2018, the Company invented the first analgesic small molecule that selectively activated the alpha3 glycine receptor, an ion channel in the spinal cord that regulates a critical anti-nociceptive pathway. In 2018, the Company licensed this technology to Kalytera Therapeutics, Ltd. in return for cash and equity.

https://www.salzmangrp.com/about-us/history/

<< Previous

Bullboard Posts

Next >>

Eminent acquires promising Nevada gold project